Janssen Pharmaceutical Companies of Johnson And: U.S. FDA Approves AKEEGA, the First-AndOnly Dual Action Tablet for the Treatment of Patients With BRCA-Positive Metastatic Castration-Resistant Prostate Cancer
August 12, 2023
August 12, 2023
CHICAGO, Illinois, Aug. 12 (TNSres) -- The Janssen Pharmaceutical Companies of Johnson and Johnson issued the following news release on Aug. 11, 2023:
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food & Drug Administration (FDA) has approved AKEEGA(TM) (niraparib and abiraterone acetate), the first-and-only dual action tablet combining a PARP inhibitor with abiraterone acetate, given with prednisone, for the treatment of adult patie . . .
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food & Drug Administration (FDA) has approved AKEEGA(TM) (niraparib and abiraterone acetate), the first-and-only dual action tablet combining a PARP inhibitor with abiraterone acetate, given with prednisone, for the treatment of adult patie . . .